日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

辅助S-1联合内分泌治疗ER阳性、HER2阴性原发性乳腺癌:POTENT试验后预后调查

Takada, Masahiro; Saji, Shigehira; Ueno, Takayuki; Masuda, Norikazu; Ishiguro, Hiroshi; Ishida, Takanori; Saeki, Toshiaki; Imoto, Shigeru; Ohno, Shinji; Iwata, Hiroji; Sugie, Tomoharu; Aogi, Kenjiro; Takayama, Shin; Sato, Nobuaki; Kai, Yuichiro; Kitada, Masahiro; Nakamura, Rikiya; Watanabe, Kenichi; Matsuyama, Yutaka; Toi, Masakazu

Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial

转移性乳腺癌原发肿瘤切除联合全身治疗与单纯全身治疗的疗效比较(JCOG1017,PRIM-BC):一项随机临床试验

Shien, Tadahiko; Hara, Fumikata; Aogi, Kenjiro; Yanagida, Yasuhiro; Tsuneizumi, Michiko; Yamamoto, Naohito; Matsumoto, Hiroshi; Suto, Akihiko; Watanabe, Kenichi; Harao, Michiko; Kanbayashi, Chizuko; Itoh, Mitsuya; Kadoya, Takayuki; Anan, Keisei; Maeda, Shigeto; Sasaki, Keita; Ogawa, Gakuto; Saji, Shigehira; Fukuda, Haruhiko; Iwata, Hiroji

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

奥氮平用于治疗接受曲妥珠单抗德鲁替康治疗的乳腺癌患者的恶心和呕吐:ERICA 研究的简明语言摘要

Sakai, Hitomi; Tsurutani, Junji; Ozaki, Yukinori; Ishiguro, Hiroshi; Nozawa, Kazuki; Yamanaka, Takashi; Aogi, Kenjiro; Matsumoto, Koji; Iwasa, Tsutomu; Tokiwa, Mariko; Tsuneizumi, Michiko; Miyoshi, Yasuo; Kitagawa, Chiyoe; Yamamoto, Mitsugu; Takano, Yuko; Imamura, Chiyo K; Chiba, Yasutaka; Takiguchi, Daisuke; Ezumi, Takayuki; Takano, Toshimi

An Initiative for the Early Detection and Intervention of Postoperative Lymphedema in Patients With Breast Cancer by Occupational and Physical Therapists

由职业治疗师和物理治疗师发起的乳腺癌患者术后淋巴水肿早期检测和干预倡议

Akezaki, Yoshiteru; Nakata, Eiji; Kikuuchi, Masato; Tominaga, Ritsuko; Kurokawa, Hideaki; Aogi, Kenjiro; Sugihara, Shinsuke

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

一项针对HR阳性/HER2阴性晚期乳腺癌患者的帕博西尼联合他莫昔芬的3期研究(PATHWAY)

Noguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan

TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts

TP53 特征预测乳腺癌新辅助化疗后的病理完全缓解:一项采用前瞻性研究队列的观察性和验证性研究

Takahashi, Shin; Sato, Nobuaki; Kaneko, Kouji; Masuda, Norikazu; Kawai, Masaaki; Hirakawa, Hisashi; Nomizu, Tadashi; Iwata, Hiroji; Ueda, Ai; Ishikawa, Takashi; Bando, Hiroko; Inoue, Yuka; Ueno, Takayuki; Ohno, Shinji; Kubo, Makoto; Yamauchi, Hideko; Okamoto, Masahiro; Tokunaga, Eriko; Kamigaki, Shunji; Aogi, Kenjiro; Komatsu, Hideaki; Kitada, Masahiro; Uemoto, Yasuaki; Toyama, Tatsuya; Yamamoto, Yutaka; Yamashita, Toshinari; Yanagawa, Takehiro; Yamashita, Hiroko; Matsumoto, Yoshiaki; Toi, Masakazu; Miyashita, Minoru; Ishida, Takanori; Fujishima, Fumiyoshi; Sato, Satoko; Yamaguchi, Takuhiro; Takahashi, Fumiaki; Ishioka, Chikashi

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

新辅助曲妥珠单抗-美坦新+帕妥珠单抗(T-DM1+P)和多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗(TCbHP)治疗HER2阳性原发性乳腺癌的长期疗效:随机2期JBCRG20研究(Neo-peaks)的结果

Takano, Toshimi; Masuda, Norikazu; Ito, Mitsuya; Inoue, Kenichi; Tanabe, Yuko; Kawaguchi, Kousuke; Yasojima, Hiroyuki; Bando, Hiroko; Nakamura, Rikiya; Yamanaka, Takashi; Ishida, Kazushige; Aruga, Tomoyuki; Yanagita, Yasuhiro; Tokunaga, Eriko; Aogi, Kenjiro; Ohno, Shinji; Kasai, Hiroi; Kataoka, Tatsuki R; Morita, Satoshi; Toi, Masakazu

2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis

2023年日本临床肿瘤学会止吐临床实践指南更新

Iihara, Hirotoshi; Abe, Masakazu; Wada, Makoto; Iino, Keiko; Akechi, Tatsuo; Imamura, Chiyo K; Okuyama, Ayako; Ozawa, Keiko; Kim, Yong-Il; Sasaki, Hidenori; Satomi, Eriko; Takeda, Masayuki; Tanaka, Ryuhei; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi; Higashi, Takahiro; Boku, Narikazu; Matsumoto, Koji; Matsumoto, Yoko; Okita, Kenji; Yamamoto, Nobuyuki; Aogi, Kenjiro

Internal mammary node abnormality in imaging studies and treatment outcomes in patients with breast cancer

影像学检查中内乳淋巴结异常与乳腺癌患者治疗结果的关系

Makita, Kenji; Hamamoto, Yasushi; Kanzaki, Hiromitsu; Nagasaki, Kei; Aogi, Kenjiro

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

纳武利尤单抗联合阿贝西利加内分泌治疗治疗 HR 阳性 HER2 阴性转移性乳腺癌患者的疗效、安全性和生物标志物分析:一项 II 期研究(WJOG11418B NEWFLAME 试验)

Masuda, Jun; Sakai, Hitomi; Tsurutani, Junji; Tanabe, Yuko; Masuda, Norikazu; Iwasa, Tsutomu; Takahashi, Masato; Futamura, Manabu; Matsumoto, Koji; Aogi, Kenjiro; Iwata, Hiroji; Hosonaga, Mari; Mukohara, Toru; Yoshimura, Kiyoshi; Imamura, Chiyo K; Miura, Sakiko; Yamochi, Toshiko; Kawabata, Hidetaka; Yasojima, Hiroyuki; Tomioka, Nobumoto; Yoshimura, Kenichi; Takano, Toshimi